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Abstract
Interleukin (IL)-33 and its unique receptor, ST2, play a pivotal role in the immune response
to infection and stress. However, there have been conflicting reports of the role of IL-33 in
cardiovascular disease (CVD) and the potential of this axis in differentiating CVD patients
and controls and with CVD disease severity, remains unclear.
Aims
1) To quantify differences in circulating IL-33 and/or sST2 levels between CVD patients ver-
sus controls. 2) Determine association of these biomarkers with mortality in CVD and com-
munity cohorts.
Methods and results
Using Pubmed/MEDLINE, Web of Science, Prospero and Cochrane databases, systematic
review of studies published on IL-33 and/or sST2 levels in patients with CVD (heart failure,
acute coronary syndrome, atrial fibrillation, stroke, coronary artery disease and hyperten-
sion) vs controls, and in cohorts of each CVD subtype was performed. Pooled standardised
mean difference (SMD) of biomarker levels between CVD-cases versus controls and hazard
ratios (HRs) for risk of mortality during follow-up in CVD patients, were assessed by random
effects meta-analyses. Heterogeneity was evaluated with random-effects meta-regres-
sions. From 1071 studies screened, 77 were meta-analysed. IL-33 levels were lower in HF
and CAD patients vs controls, however levels were higher in stroke patients compared con-
trols [Meta-SMD 1.455, 95% CI 0.372–2.537; p = 0.008, I2 = 97.645]. Soluble ST2 had a
stronger association with risk of all-cause mortality in ACS (Meta-multivariate HR 2.207,
95% CI 1.160–4.198; p = 0.016, I2 = 95.661) than risk of all-cause mortality in HF (Meta-mul-
tivariate HR 1.425, 95% CI 1.268–1.601; p<0.0001, I2 = 92.276). There were insufficient
data to examine the association of IL-33 with clinical outcomes in CVD.
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Conclusions
IL-33 and sST2 levels differ between CVD patients and controls. Higher levels of sST2 are
associated with increased mortality in individuals with CVD. Further study of IL-33/ST2 in
cardiovascular studies is essential to progress diagnostic and therapeutic advances related
to IL-33/ST2 signalling.
Introduction
Cardiovascular diseases (CVDs) are the leading causes of death and morbidity worldwide. In
the UK alone, CVDs caused 167,116 (27.1%) of all deaths in 2018 [1]. Currently there is an
unmet need to improve identification of patients with CVD, enhance prognostic prediction of
patients who are at risk of poor outcomes and improve understanding of the underlying
pathophysiology of CVD to enable development of novel treatment targets.
Inflammatory pathways play an important role in atherosclerosis, and an improved under-
standing of the signalling molecules involved has translated to promising therapeutics such as
the CANTOS trial targeting Interleukin-1β [2]. Interleukin-33 (IL-33) is another member of
the Interleukin-1 family of cytokines that has emerged as a target of interest in a variety of
inflammatory conditions including asthma, chronic obstructive pulmonary disease, and most
recently Coronavirus disease 2019 (COVID-19) [3–5]. Despite these advances, pre-clinical
studies on the role of IL-33 in cardiovascular health have yielded contrasting data, suggesting
both cardioprotective and detrimental effects of IL-33 [6].
Previous studies have elucidated the biological function of IL-33 as constitutively expressed
and stored in complex with chromatin in the nucleus of epithelial cells and vascular endothe-
lium [7, 8]. In response to cellular injury or necrosis, the chromatin-IL-33 complex is released
into the extracellular space as an alarmin signal. When bound to ST2L (transmembrane ligand
of IL-33’s unique receptor, ST2) on target cell membranes, it triggers an intracellular signalling
cascade, augmented by the presence of histones [9]. IL-33 induces varied immune cells and
can upregulate the release of cytokines such as IL-6 and IL-8 [10]. IL-33’s unique receptor,
ST2, exists in a transmembrane (ST2L) and soluble form (sST2). Major sources of ST2L and
sST2 include endothelial cells of the aorta and coronary arteries as well as immune cells such
as T cells [11, 12]. The transmembrane form of ST2 enables IL-33’s signalling activity, whilst
sST2 acts as a decoy receptor binding IL-33, to dampen its effects.
Soluble ST2 has been evaluated in a number of clinical CVD studies and is a Food and
Drug Administration (FDA) approved prognostic biomarker of mortality in chronic heart fail-
ure patients [13]. Previous meta-analyses have shown that sST2 has diagnostic value for heart
failure and is prognostic for all-cause mortality in heart failure, coronary artery disease and fol-
lowing aortic valve replacement [14–19]. However, there is a paucity of clinical studies on IL-
33, which is likely due to difficultly measuring circulating levels [20].
To our knowledge, no previous meta-analysis has examined IL-33 itself, or with sST2 as
biomarkers across the spectrum of CVDs. In this systematic review and meta-analysis, we
sought to systematically evaluate data to establish the clinical significance of the IL-33/ST2 axis
in CVD. Firstly, to determine the value of circulating IL-33 and/or sST2 levels in differentiat-
ing people with CVDs versus those without. Secondly, to determine the association of IL-33
and/or sST2 biomarker levels with clinical outcomes of mortality or MACE (composite end-
point of death or adverse cardiovascular event) in CVD or community cohorts.
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Before beginning the search process, we registered this systematic review and meta-analysis on
Prospero (https://www.crd.york.ac.uk/prospero/ - (CRD42020168206).
MF devised the study question and design and contributed to data collection and analysis,
and co-authored the final manuscript. IBW contributed to study design and manuscript writ-
ing. HP contributed to statistical analysis. YS undertook data collection, data analysis and sta-
tistical analysis and wrote the original draft of the manuscript.
The authors carried out independent searches in Pubmed (including MEDLINE), Web of
Science, Cochrane Library and Prospero databases in September 2020. The search terms were
one of IL-33/Interleukin-33/ST2 combined with one of cardiovascular disease, stroke, myocar-
dial infarction, heart failure, coronary disease, ischaemic heart disease and hypertension. The
same search terms were entered into each database.
During primary screening of articles, the title and abstract were assessed for relevance to
the topic, English language, full text availability and inclusion/exclusion criteria. All datasets
included in this systematic review and meta-analysis were in vivo human studies that involved
measurement of plasma or serum levels of IL-33 or sST2 as a continuous variable (not categor-
ical) and a subtype of CVD (based on clinical diagnosis and/or supporting clinical test data of
this diagnosis). Full inclusion/exclusion criteria are available in S1 File. Studies were under-
taken in countries across the world, with China being the largest single source. Meta-analyses
were performed for CVDs versus controls based on CVD search terms listed above. Studies
were categorised into acute coronary syndrome (ACS, including unstable angina and myocar-
dial infarction), coronary artery disease (CAD, including stable angina), atrial fibrillation
(AF), systemic hypertension, acute heart failure (defined as hospital admission with decom-
pensation or new hospital diagnosis) or chronic heart failure (CHF). Individual meta-analysis
stratified by these distinct CVD subtypes vs controls were performed if there were�2 eligible
studies. The association of IL-33 and/or sST2 biomarker levels with clinical outcomes of all-
cause mortality or MACE (composite endpoint of death or adverse cardiovascular event) were
evaluated in CVD as well as community population studies.
Data extraction and quality assessment
The authors independently used the PRISMA statement as the basis for extracting and recording
data from eligible articles. Data extracted includes circulating biomarker levels and associated
standard deviation or confidence intervals, inclusion and exclusion criteria of the study, study
type, sample size, hazard ratios, follow-up period, age and outcomes. Where median biomarker
levels and quartile values were reported, they were converted to mean and standard deviations
with the method reported by Wan et al. 2014 to enable standardisation across studies [21]. Stud-
ies reporting data that could not be converted to mean and standard deviation were not included
in analyses where the outcome was standardised mean difference. Full data extracted, including
adjustment factors of multivariate HR analysis are available in (S3 Table in S3 File). Disagree-
ments over the eligibility of a study and its data were resolved through discussion.
Study quality was assessed using a modified version of the Quality Assessment of Diagnos-
tic Accuracy Studies 2 (QUADAS-2) criteria. Full criteria are available in S2 File.
Statistical analysis
The primary outcomes were weighted pooled standardised mean difference (SMD) of bio-
marker levels comparing cases vs controls (Meta-SMD) and weighted pooled hazard ratios
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(Meta-HR) for occurrence of all-cause mortality, cardiovascular death and MACE during fol-
low up calculated using random effects models. Only studies presenting univariate or multi-
variate HRs per (log) unit increase in biomarker levels were accepted for Meta-HR.
Data selected for meta-analysis were displayed in forest plots showing the SMDs or HRs of
individual studies and the overall Meta-value. Heterogeneity was assessed using I2 statistics
and where possible, meta-regression was carried out to assess the effect of cohort age (mean or
median), length of follow up (mean or median), publication year, biomarker assay type (Pres-
age ST2 or not) [13]. Statistical analysis was carried out using Comprehensive Meta-Analysis
3.0 software.
Results and discussion
The flow diagram summary of search results is shown in Fig 1. 4745 articles were identified,
and, after duplicates were removed and screening was carried out, remaining studies were sys-
tematically screened, yielding 77 studies (62075 participants) for meta-analysis and systematic
review. The vast majority of included studies assessed participants between 60–80 years old
and heart failure was the most reported disease type (47% of studies). A full table detailing the
studies can be found in S3 File.
IL-33 and sST2 levels in CVD patients versus controls
IL-33. In analysis of two CAD studies with a total sample size of 156 subjects, patients had
lower IL-33 levels than controls, Meta-SMD of -0.972, 95% CI -1.307-(-0.638); p<0.0001, I2 =
0.0. Additionally, analysis of two HF studies with 281 total subjects showed that patients had
lower IL-33 levels than controls, Meta-SMD of -0.683, 95% CI -1.213-(-0.153); p = 0.012, I2 =
68.467 (Fig 2). ACS patients also had lower IL-33 levels compared to controls (four studies
with total sample size of 331), although this did not reach statistical significance: Meta-SMD of
-1.373, 95% CI -2.978–0.231; p = 0.093, I2 = 97.379.
Fig 1. Flow chart of search strategy. Summary of search strategy and eligible study selection.
https://doi.org/10.1371/journal.pone.0259026.g001
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Five studies reported (908 total subjects, sample size ranging from 90–287) IL-33 levels in
acute ischaemic stroke patients vs controls. Stroke patients had consistently higher IL-33 levels
than healthy controls [Meta-SMD 1.455, 95% CI 0.372–2.537; p = 0.008, I2 = 97.645] (Fig 3).
Two studies (449 subjects) showed that stroke patients who had favourable outcomes (Barthel
Index score above 85 or 90 respectively at 3 months and 1 year after admission respectively)
had higher baseline IL-33 levels than those who did not: Meta-SMD 0.564, 95% CI 0.356–
0.772; p<0.0001, I2 = 0.0 [22, 23].
There was no difference in IL-33 levels between hypertension patients and controls (three
studies with total sample size of 710): Meta-SMD of -0.024, 95% CI -0.443–0.395; p = 0.912, I2
= 81.874.
There were no clinical studies to evaluate the association of IL-33 with clinical outcomes
based on the study’s inclusion/exclusion criteria.
sST2. Analysis of two CAD studies (408 subjects) showed patients had no difference in
levels of sST2 compared with controls: Meta-SMD of 0.033 [95% CI -0.197–0.264; p = 0.778, I2
= 16.127].
Only one study across the meta-analysis of all CVD subtypes, Demyanets et al. 2014 in
CAD, reported patients having lower sST2 levels than controls [24]. Four studies with a total
of 470 subjects reported that HF patients had higher sST2 levels than controls: Meta-SMD of
2.178 [95% CI 0.653–3.704; p = 0.005, I2 = 96.939].
Meta-analyses of sST2 performed within ACS vs controls (total sample size of 1153) are
shown in Fig 4, where ACS patients had higher levels of sST2 compared with controls: Meta-
SMD of 0.92 [95% CI 0.632–1.208; p<0.0001, I2 = 77.797].
Acute ischaemic stroke patients also had higher sST2 levels compared to controls, reported
from two studies with a sample size of 190 and 221, although this did not reach statistical sig-
nificance [Meta-SMD 3.96, 95% CI -0.839–8.760; p = 0.106, I2 = 99.334]. Additionally, AF
Fig 2. Summary forest plots showing the Meta-SMD and 95% CI of IL-33 levels in HF patients and healthy
controls. The Meta-SMD in the random effects model is shown by the black diamond at the bottom. The vertical line
at 0.00 is the border for significance.
https://doi.org/10.1371/journal.pone.0259026.g002
Fig 3. Summary forest plots showing the Meta-SMD and 95% CI of IL-33 levels in stroke patients and healthy
controls. The Meta-SMD in the random effects model is shown by the black diamond at the bottom. The vertical line
at 0.00 is the border for significance.
https://doi.org/10.1371/journal.pone.0259026.g003
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patients also had higher sST2 levels than controls (Fig 5, 704 subjects from three studies):
Meta-SMD of 2.825 [95% CI 0.607–5.043; p = 0.013, I2 = 99.132].
Association of sST2 levels and clinical outcomes in CVD and community
cohorts
For CAD, three studies following 4371 patients for up to 12.3 years, showed that baseline sST2
levels of patients who died during follow up were higher than survivors, Meta-SMD of 0.502
[95% CI 0.273–0.730; p<0.0001, I2 = 88.78].
Soluble ST2 had a stronger association with risk of all-cause mortality in ACS (Four data-
sets, Meta-multivariate HR 2.207, 95% CI 1.160–4.198; p = 0.016, I2 = 95.661) than risk of all-
cause mortality in HF (Fifteen datasets, Meta-multivariate HR 1.425, 95% CI 1.268–1.601;
p<0.0001, I2 = 92.276).
Two acute ischaemic stroke studies also evaluated baseline sST2 levels in patients stratified by
survival status. During 90 days follow up, 132 patients who died had higher baseline sST2 levels
than the 903 who survived [Meta-SMD 1.151, 95% CI 0.670–1.633, p<0.0001, I2 = 83.474] [25, 26].
Five studies followed 18264 individuals from community cohorts for up to 15 years to eval-
uate risk of adverse events (including all-cause mortality, MACE, and occurrence of specific
CVDs, such as development of AF) per log unit increase of sST2 levels (Fig 6). The Meta-mul-
tivariate HR was 1.035 [95% CI 1.005–1.065; p = 0.021, I2 = 2.114].
Heterogeneity and meta-regression
Most of the studies had high heterogeneity (I2 value greater than 50%). For studies with high
heterogeneity, meta-regression analyses (assessing the effect of age, follow up time, publication
Fig 4. Summary forest plots showing the Meta-SMD and 95% CI of sST2 levels in ACS patients and healthy
controls. The Meta-HR in the random effects model is shown by the black diamond at the bottom. The vertical line at
1 is the border for significance.
https://doi.org/10.1371/journal.pone.0259026.g004
Fig 5. Summary forest plots showing the Meta-SMD and 95% CI of sST2 levels in AF patients and healthy
controls. The Meta-HR in the random effects model is shown by the black diamond at the bottom. The vertical line at
1 is the border for significance.
https://doi.org/10.1371/journal.pone.0259026.g005
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year and sST2 assay) did not identify covariates that reduced I2 value to below 50% in the vast
majority of analyses.
Discussion
We used systematic review methods to evaluate the associations between circulating levels of
IL-33 and/or sST2 and CVD subtypes, and associations between these biomarkers and out-
comes of mortality and MACE in CVD patients as well as community populations. Our main
findings were that patients from the spectrum of CVDs have higher sST2 levels compared with
healthy controls and that incremental increases in sST2 are associated with poor clinical out-
comes of mortality and MACE over several years follow up in both CVD and community-
based cohorts. We observed lower IL-33 levels in HF, CAD and ACS patients compared with
controls. In contrast, higher IL-33 levels were recorded in acute ischaemic stroke patients com-
pared with controls. There were insufficient data to examine the association of IL-33 with clin-
ical outcomes in CVD or community populations.
This is the first meta-analysis to systematically evaluate both IL-33 and sST2 levels across
the spectrum of CVDs. It suggests that peripheral circulating sST2 measurement may have
clinical value in differentiating patients with CVD versus controls without CVD. The greatest
difference in sST2 levels compared with controls was observed in AF and CHF.
Soluble ST2 is an FDA approved biomarker to evaluate prognosis of mortality in chronic
heart failure. Previous meta-analyses of sST2 have also been performed in CAD and post-aor-
tic valve replacement patients [14, 16, 18, 19] and showed that higher sST2 levels were associ-
ated with poor clinical outcomes in these populations. The current meta-analysis shows sST2
is associated with risk of poor outcomes of mortality, MACE and adverse cardiovascular events
in a wide definition of CVD patients as well as community populations without identified car-
diovascular disease. It suggests sST2 may also have value as a risk biomarker in CVD patients
generally (besides chronic heart failure) and in community cohorts, although notably to a
lesser extent than in CVD. Despite methodological differences between a meta-analysis by Liu
et al. of ST2 (in ACS and CAD patients only) and our current study, meta-multivariate HRs of
all-cause mortality in ACS patients are similar, with a respective meta-multivariate HR of 2.48,
(95% CI 1.99–2.97) for Liu et al. and HR 2.207, (95% CI 1.160–4.198) in this current study
[19].
Fig 6. Summary forest plot showing the multivariate Meta-HR and 95% CI for risk of any adverse cardiovascular
events in community populations and its relation to sST2 levels. The Meta-HR in the random effects model is
shown by the black diamond at the bottom. The vertical line at 1 is the border for significance. AF = atrial fibrillation,
ACM = all-cause mortality, CV = cardiovascular, HF = heart failure, CVD = cardiovascular disease, CHD = coronary
heart disease, MI = myocardial infarction, MACE = major adverse cardiovascular events.
https://doi.org/10.1371/journal.pone.0259026.g006
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To the best of our knowledge, this is the first meta-analysis of CVD studies of IL-33 and
included 1638 participants. It suggests potential clinical value in measurement of IL-33, in that
IL-33 levels were lower in CAD, HF and ACS patients versus controls. However, it must be
noted other individual studies (not included in this meta-analysis after considering inclusion/
exclusion criteria) have shown different results, with IL-33 levels being higher in heart failure
patients compared with controls [27, 28]. Interestingly, IL-33 levels were higher in stroke
patients compared with controls; in contrast to findings from other CVD subtypes, based on
five studies with a sample size of 908. The reasons for these contrasting results in stroke are
currently unclear and require further investigation. The low sample size of such studies indi-
cate it would be premature to suggest a different role for IL-33 in cerebrovascular disease com-
pared to other cardiovascular diseases. Moreover, a major drawback to advancing
understanding of IL-33 in human cardiovascular health and disease is that often levels are
below the detection limit of an assay and there is wide divergence in the methodology of how
studies processed and analysed IL-33 samples in the current published literature [20]. In this
meta-analysis, several IL-33 studies were not included due to levels of IL-33 being below the
detection limit of the assay [24, 29, 30]. A further point of consideration is that IL-33 exists
extracellularly in both full length and cleaved forms and cleavage may either enhance its
potency or inactivate it depending on whether serine proteases or apoptotic caspases facilitate
cleavage. In this meta-analysis, the included studies did not identify whether full length or
cleaved forms of IL-33 were measured.
This meta-analysis showed that circulating IL-33 levels were much lower than sST2 levels,
which reflects sST2’s role as a decoy receptor to limit IL-33 activity. Moreover, IL-33 exerts its
effects in an autocrine/paracrine manner, and is quickly oxidised after its release from cells,
making it more difficult to detect in circulation [31]. Due to these factors, sST2 is likely a
much more clinically useful and attainable biomarker to measure in clinical studies as shown
by the results of this meta-analysis. Overall, it remains to be elucidated whether IL-33 itself is
cardioprotective or deleterious as suggested by contrasting pre-clinical animal studies. There is
a need to advance understanding of the IL-33/ST2 axis in CVDs, and studying local tissue
expression of IL-33 and the effects of blocking IL-33 or ST2 may be helpful [32, 33]. Of inter-
est, a loss of function in the IL-33 gene has been shown to be protective against asthma in
humans, with no harmful effects (i.e. cardiovascular abnormalities) reported [34].
This study has several limitations. The first is the low number of IL-33 clinical studies avail-
able which limits conclusions we can draw regarding IL-33’s role in cardiovascular health.
Additionally, differences in the sensitivity of IL-33 assays are a potential hindrance for repeat-
ability and interpretation of clinical studies. The second is that Meta-multivariate HRs
reported are adjusted for different factors at the individual study level that could impact IL-33/
sST2 expression (e.g. age, gender, comorbidities, body mass index, and levels of other inflam-
matory biomarkers). The majority of studies adjusted for age and gender; and many included
extensive adjustment for other cardiovascular risk factors. Furthermore, the length of storage
time for biomarkers before analysis varied, which may impact biomarker stability.
Conclusions
In summary, this meta-analysis is the first to analyse the role of both IL-33 and sST2 across the
spectrum of human CVDs. We showed that sST2 has diagnostic and prognostic value over sev-
eral years of follow up across the spectrum of CVDs. Similarly, IL-33 shows some promise as a
biomarker to differentiate between CVD patients and controls. Meta-SMDs showed that IL-33
levels are lower in HF and CAD patients compared to controls, while the reverse was observed
in stroke patients. This observation and the small sample size means that further clinical
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studies are needed to determine if measurement of circulating IL-33 has diagnostic or prog-
nostic value (similar to that of sST2) across the spectrum of CVD subtypes.
Supporting information
S1 File. Inclusion/exclusion criteria.
(PDF)
S2 File. QUADAS-2 scoring criteria.
(PDF)
S3 File. Table of studies.
(PDF)
S1 Checklist. PRISMA 2009 checklist.
(PDF)
Author Contributions
Conceptualization: Yuan Sun, Ian Wilkinson, Marie Fisk.
Data curation: Yuan Sun.
Formal analysis: Yuan Sun.
Funding acquisition: Ian Wilkinson, Marie Fisk.
Methodology: Yuan Sun.
Software: Yuan Sun.
Supervision: Ian Wilkinson, Marie Fisk.
Writing – original draft: Yuan Sun.
Writing – review & editing: Holly Pavey, Ian Wilkinson, Marie Fisk.
References
1. BHF. Heart and circulatory disease statistics 2020: BHF; 2020 [cited 2020 01/06/2020]. Available from:
https://www.bhf.org.uk/what-we-do/our-research/heart-statistics/heart-statistics-publications/
cardiovascular-disease-statistics-2020.
2. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory
Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12):1119–31. https://
doi.org/10.1056/NEJMoa1707914 PMID: 28845751
3. Gabryelska A, Kuna P, Antczak A, Bialasiewicz P, Panek M. IL-33 Mediated Inflammation in Chronic
Respiratory Diseases-Understanding the Role of the Member of IL-1 Superfamily. Front Immunol.
2019; 10:692. https://doi.org/10.3389/fimmu.2019.00692 PMID: 31057533
4. Stanczak Sea. IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19
convalescent individuals: medRxiv; 2020 [cited 2020. Pre-print]. Available from: https://www.medrxiv.
org/content/10.1101/2020.07.09.20148056v1.
5. Chen WY, Li LC, Yang JL. Emerging Roles of IL-33/ST2 Axis in Renal Diseases. Int J Mol Sci. 2017; 18
(4). https://doi.org/10.3390/ijms18040783 PMID: 28387719
6. Altara R, Ghali R, Mallat Z, Cataliotti A, Booz GW, Zouein FA. Conflicting vascular and metabolic impact
of the IL-33/sST2 axis. Cardiovasc Res. 2018; 114(12):1578–94. https://doi.org/10.1093/cvr/cvy166
PMID: 29982301
7. Gautier V, Cayrol C, Farache D, Roga S, Monsarrat B, Burlet-Schiltz O, et al. Extracellular IL-33 cyto-
kine, but not endogenous nuclear IL-33, regulates protein expression in endothelial cells. Sci Rep.
2016; 6:34255. https://doi.org/10.1038/srep34255 PMID: 27694941
PLOS ONE IL-33/ST2 axis in cardiovascular disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0259026 November 1, 2021 9 / 11
8. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus
of endothelial cells and epithelial cells in vivo: a novel ’alarmin’? PLoS One. 2008; 3(10):e3331. https://
doi.org/10.1371/journal.pone.0003331 PMID: 18836528
9. Travers J, Rochman M, Miracle CE, Habel JE, Brusilovsky M, Caldwell JM, et al. Chromatin regulates
IL-33 release and extracellular cytokine activity. Nat Commun. 2018; 9(1):3244. https://doi.org/10.1038/
s41467-018-05485-x PMID: 30108214
10. Pinto SM, Subbannayya Y, Rex DAB, Raju R, Chatterjee O, Advani J, et al. A network map of IL-33 sig-
naling pathway. J Cell Commun Signal. 2018; 12(3):615–24. https://doi.org/10.1007/s12079-018-0464-
4 PMID: 29705949
11. Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, et al. Components of the
interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells
of the cardiac vasculature. J Mol Cell Cardiol. 2013; 60:16–26. https://doi.org/10.1016/j.yjmcc.2013.03.
020 PMID: 23567618
12. Lu J, Kang J, Zhang C, Zhang X. The role of IL-33/ST2L signals in the immune cells. Immunol Lett.
2015; 164(1):11–7. https://doi.org/10.1016/j.imlet.2015.01.008 PMID: 25662624
13. FDA. Substantial Equivalence Determination Decision Summary Assay Only Template 2020 [cited
2020 17/07/2020]. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K111452.pdf.
14. Aimo A, Vergaro G, Passino C, Ripoli A, Ky B, Miller WL, et al. Prognostic Value of Soluble Suppression
of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. JACC Heart Fail. 2017; 5(4):280–6.
https://doi.org/10.1016/j.jchf.2016.09.010 PMID: 27816512
15. Huang Z, Zhong J, Ling Y, Zhang Y, Lin W, Tang L, et al. Diagnostic value of novel biomarkers for heart
failure: A meta-analysis. Herz. 2020; 45(1):65–78. https://doi.org/10.1007/s00059-018-4702-6 PMID:
29700556
16. Tse G, Ip C, Luk KS, Gong M, Ting YY, Lakhani I, et al. Prognostic value of soluble ST2 postaortic valve
replacement: a meta-analysis. Heart Asia. 2018; 10(1):e010980. https://doi.org/10.1136/heartasia-
2017-010980 PMID: 29636828
17. Huang DH, Sun H, Shi JP. Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Fail-
ure. Chin Med J (Engl). 2016; 129(5):570–7. https://doi.org/10.4103/0366-6999.177000 PMID:
26904992
18. Aimo A, Vergaro G, Ripoli A, Bayes-Genis A, Pascual Figal DA, de Boer RA, et al. Meta-Analysis of Sol-
uble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. JACC Heart Fail. 2017; 5
(4):287–96. https://doi.org/10.1016/j.jchf.2016.12.016 PMID: 28189578
19. Liu N, Hang T, Gao X, Yang W, Kong W, Lou Q, et al. The association between soluble suppres-
sion of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-
analysis. PLoS One. 2020; 15(9):e0238775. https://doi.org/10.1371/journal.pone.0238775 PMID:
32886697
20. Ketelaar ME, Nawijn MC, Shaw DE, Koppelman GH, Sayers I. The challenge of measuring IL-33 in
serum using commercial ELISA: lessons from asthma. Clin Exp Allergy. 2016; 46(6):884–7. https://doi.
org/10.1111/cea.12718 PMID: 26850082
21. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample
size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. https://doi.org/
10.1186/1471-2288-14-135 PMID: 25524443
22. Qian L, Yuanshao L, Wensi H, Yulei Z, Xiaoli C, Brian W, et al. Serum IL-33 Is a Novel Diagnostic and
Prognostic Biomarker in Acute Ischemic Stroke. Aging Dis. 2016; 7(5):614–22. https://doi.org/10.
14336/AD.2016.0207 PMID: 27699084
23. Li XM, Wang XY, Feng XW, Shao MM, Liu WF, Ma QQ, et al. Serum interleukin-33 as a novel marker
for long-term prognosis and recurrence in acute ischemic stroke patients. Brain Behav. 2019; 9(9):
e01369. https://doi.org/10.1002/brb3.1369 PMID: 31397082
24. Demyanets S, Speidl WS, Tentzeris I, Jarai R, Katsaros KM, Farhan S, et al. Soluble ST2 and interleu-
kin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One.
2014; 9(4):e95055. https://doi.org/10.1371/journal.pone.0095055 PMID: 24751794
25. Dieplinger B, Bocksrucker C, Egger M, Eggers C, Haltmayer M, Mueller T. Prognostic Value of Inflam-
matory and Cardiovascular Biomarkers for Prediction of 90-Day All-Cause Mortality after Acute Ische-
mic Stroke-Results from the Linz Stroke Unit Study. Clin Chem. 2017; 63(6):1101–9. https://doi.org/10.
1373/clinchem.2016.269969 PMID: 28348074
26. Wolcott Z, Batra A, Bevers MB, Sastre C, Khoury J, Sperling M, et al. Soluble ST2 predicts outcome
and hemorrhagic transformation after acute stroke. Ann Clin Transl Neurol. 2017; 4(8):553–63. https://
doi.org/10.1002/acn3.435 PMID: 28812045
PLOS ONE IL-33/ST2 axis in cardiovascular disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0259026 November 1, 2021 10 / 11
27. Zhang HF, Xie SL, Chen YX, Mai JT, Wang JF, Zhu WL, et al. Altered serum levels of IL-33 in patients
with advanced systolic chronic heart failure: correlation with oxidative stress. J Transl Med. 2012;
10:120. https://doi.org/10.1186/1479-5876-10-120 PMID: 22682001
28. Luo NS, Zhang HF, Liu PM, Lin YQ, Huang TC, Yang Y, et al. [Diagnostic value of combining serum sol-
uble ST2 and interleukin-33 for heart failure patients with preserved left ventricular ejection fraction].
Zhonghua Xin Xue Guan Bing Za Zhi. 2017; 45(3):198–203. https://doi.org/10.3760/cma.j.issn.0253-
3758.2017.03.006 PMID: 28316175
29. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST-ele-
vation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring
and NT-proBNP. Am Heart J. 2011; 161(6):1163–70. https://doi.org/10.1016/j.ahj.2011.03.025 PMID:
21641364
30. Dhillon OS, Narayan HK, Khan SQ, Kelly D, Quinn PA, Squire IB, et al. Pre-discharge risk stratification
in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contempo-
rary risk markers? Int J Cardiol. 2013 ;167(5):2182–8. https://doi.org/10.1016/j.ijcard.2012.05.073
PMID: 22835988
31. Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, et al. Oxidation of the alarmin IL-33
regulates ST2-dependent inflammation. Nat Commun. 2015; 6:8327. https://doi.org/10.1038/
ncomms9327 PMID: 26365875
32. Tseng CCS, Huibers MMH, van Kuik J, de Weger RA, Vink A, de Jonge N. The Interleukin-33/ST2 Path-
way Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myo-
cardium. J Cardiovasc Transl Res. 2018; 11(1):15–21. https://doi.org/10.1007/s12265-017-9775-8
PMID: 29285671
33. Fairlie-Clarke K, Barbour M, Wilson C, Hridi SU, Allan D, Jiang HR. Expression and Function of IL-33/
ST2 Axis in the Central Nervous System Under Normal and Diseased Conditions. Front Immunol. 2018;
9:2596. https://doi.org/10.3389/fimmu.2018.02596 PMID: 30515150
34. Smith D, Helgason H, Sulem P, Bjornsdottir US, Lim AC, Sveinbjornsson G, et al. A rare IL33 loss-of-
function mutation reduces blood eosinophil counts and protects from asthma. PLoS Genet. 2017; 13(3):
e1006659. https://doi.org/10.1371/journal.pgen.1006659 PMID: 28273074
PLOS ONE IL-33/ST2 axis in cardiovascular disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0259026 November 1, 2021 11 / 11
